natgillin/translations-raw huggingface dataset:
At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine 100 units/ml group and a mean decrease of 0.8 kg in the standard care group.
Na zadnjem obisku med zdravljenjem je bilo povprečno povečanje telesne mase od izhodišča v skupini z insulinom glargin 100 enot/ml 1,4 kg in povprečno zmanjšanje v skupini s standardno oskrbo 0,8 kg.
Switch between insulin glargine 100 units/ml and Toujeo Since insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not interchangeable, switching may result in the need for a change in dose and should only be done under strict medical supervision (see section 4.2).
Prehod med insulinom glargin 100 enot/ml in zdravilom Toujeo Ker insulin glargin 100 enot/ml in zdravilo Toujeo nista bioekvivalentna in medsebojno zamenljiva, je ob prehodu lahko potrebna sprememba odmerka; takšen prehod se sme opraviti le pod strogim zdravniškim nadzorom (glejte poglavje 4.2).
As cutaneous amyloidosis may lead to insulin resistance due to poor absorption from the infiltrated site, health care professionals and patients should be informed of this event in the PI. Absorption of insulin could be improved by rotating the injection site.
Ker lahko kožna amiloidoza, zaradi slabe absorpcije iz mesta infiltracije, povzroči insulinsko rezistenco, je treba zdravstvene delavce in bolnike seznaniti s tem pojavom preko informacij o zdravilu.
Toujeo contains insulin called “insulin glargine”.
Zdravilo Toujeo vsebuje insulin, ki se imenuje “insulin glargin”.
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes with a medicinal product containing insulin glargine 100 units/ml) indicate no specific adverse effects on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine.
Velika količina podatkov o nosečnicah (več kot 1000 izidov nosečnosti z zdravilom, ki vsebuje insulin glargin 100 enot/ml ) ne kaže specifičnih neželenih učinkov insulina glargin na nosečnost; prav tako ne kaže, da bi insulin glargin povzročal specifične malformacije, fetotoksične učinke ali toksične učinke na novorojenčka.
• Your pen contains a total of 900 units of insulin.
• Vaš peresnik vsebuje vsega skupaj 900 enot insulina.
• You are taking or have stopped taking certain other medicines (see section 2, "Other medicines and Toujeo").
• Jemljete ali ste nehali jemati določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo Toujeo ").
Breast-feeding women may require adjustments in insulin dose and diet.
Nosečnice lahko potrebujejo prilagoditev odmerka insulina in prehrane.
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Zaviralci adrenergičnih receptorjev beta, klonidin, litijeve soli in alkohol lahko vpliv insulina na znižanje glukoze v krvi povečajo ali zmanjšajo.
Mixing or diluting Toujeo changes its time/action profile and mixing causes precipitation.
Mešanje ali redčenje zdravila Toujeo spremeni časovni potek delovanja; mešanje lahko povzroči precipitacijo.
With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary.
Zaradi boljše urejenosti presnove in večje občutljivosti za insulin je lahko potrebna nadaljnja prilagoditev odmerka.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Med zdravili oz. učinkovinami, ki lahko zmanjšajo učinek znižanja glukoze v krvi, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestageni, derivati fenotiazina, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, atipična antipsihotična zdravila (npr. klozapin in olanzapin) in zaviralci proteaz.
Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.
Zdravljenje sladkorne bolezni pri odraslih, mladostnikih in otrocih od 6. leta starosti naprej.
See “Pioglitazone used together with insulin”.
• Pioglitazon - Glejte "Uporaba pioglitazona skupaj z insulinom".
The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomized, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus (treated with ≤1 antidiabetic oral agent) (88% of participants).
Študija zmanjšanja izidov z uvodno uporabo glargin (ORIGIN - Outcome Reduction with Initial Glargine INtervention) je bila multicentrična, randomizirana študija s faktorskim načrtom 2 x 2, v katero je bilo vključenih 12.537 sodelujočih z velikim kardiovaskularnim (KV) tveganjem in moteno glukozo na tešče (MGT) ali moteno toleranco za glukozo (MTG) (12 % sodelujočih), ali s sladkorno boleznijo tipa 2, zdravljeno z ≤ 1 peroralnim antidiabetikom (88 % sodelujočih).
Prior to launch of Toujeo 300 units/ml in each Member State the MAH must agree the content and format of the educational programme, including communication media, distribution modalities, and any other aspects, with the National Competent Authority.
Pred prihodom zdravila Toujeo 300 enot/ml na trg v posamezni državi članici mora imetnik dovoljenja za promet z zdravilom (MAH) s pristojnim nacionalnim organom uskladiti vsebino in obliko izobraževalnega programa, vključno s sredstvi obveščanja, načinom razdeljevanja in morebitnimi drugimi vidiki.
Overall the incidence of hypoglycaemia in patients in any category was similar in both treatment groups, with 97.9% of patients in the Toujeo group and 98.2% in the insulin glargine 100 units/mL group reporting at least one event.
V celoti je bila pojavnost hipoglikemij pri bolnikih v vseh kategorijah v obeh terapevtskih skupinah podobna; o vsaj enem pojavu je poročalo 97,9 % bolnikov v skupini z zdravilom Toujeo in 98,2 % bolnikov v skupini z insulinom glarginom 100 enot/ml.
The more sustained release of insulin glargine from the Toujeo precipitate compared to insulin glargine 100 units/ml is attributable to the reduction of the injection volume by two thirds that results in a smaller precipitate surface area.
Podaljšano sproščanje insulina glargin iz precipitata zdravila Toujeo v primerjavi z insulinom glargin 100 enot/ml je mogoče pripisati zmanjšanju injicirane količine za dve tretjini: posledica tega je manjša površina precipitata.
Only use needles that are compatible for use with Toujeo (e.g. needles from BD, Ypsomed, Artsana or Owen Mumford).
Uporabljajte samo igle, ki primerne za uporabo z zdravilom Toujeo (npr. igle izdelovalcev BD, Ypsomed, Artsana ali Owen Mumford).
Participants were randomized (1:1) to receive insulin glargine 100 units/ml (n=6264), titrated to reach FPG ≤95 mg/dl (5.3 mM), or standard care (n=6273).
Preiskovance so v razmerju 1:1 randomizirali na prejemanje insulina glargin 100 enot/ml (n = 6264), titriranega tako, da je bila dosežena glukoza v plazmi na tešče ≤ 95 mg/dl (5,3 mM), ali na standardno oskrbo (n = 6273).
In the event of blocked needle, the patients must follow the instructions described in Step 3 of the Instructions for Use accompanying the package leaflet (see section 4.2 and 4.4).
Če je igla zamašena, mora bolnik slediti navodilom, opisanim v 3. koraku navodila za uporabo, ki je priložen navodilu za uporabo (glejte poglavji 4.2 in 4.4).
The prolonged duration of action of Toujeo is dependent on its injection into subcutaneous tissue.
Podaljšano delovanje zdravila Toujeo je odvisno od tega, da je zdravilo injicirano v podkožno tkivo.
• Detailed description of the modalities used for the self-administration of insulin glargine: - That insulin glargine 100 units/ml and insulin glargine 300 units/ml (Toujeo SoloStar and Toujeo
• Podroben opis načinov za samoinjiciranje insulina glargin: - Insulin glargin 100 enot/ml in insulin glargin 300 enot/ml (zdravilo Toujeo SoloStar in zdravilo
Mean change in body weight of less than 1 kg at the end of the 6-month period was observed in Toujeo-treated patients (see Table 1 and 2).
Pri bolnikih, ki so prejemali zdravilo Toujeo, so na koncu 6-mesečnega obdobja ugotovili povprečno spremembo telesne mase za manj kot 1 kg (glejte preglednici 1 in 2).
If you see insulin coming out of the needle tip, the pen is ready to use.
Če vidite, da je iz konice igle prišel insulin, je peresnik pripravljen za uporabo.
Taking into account the PRAC Assessment Report on the PSUR(s) for insulin glargine, the scientific conclusions of CHMP are as follows:
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za insulin glargin je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
The superiority of Toujeo over insulin glargine 100 units/ml in lowering the risk of confirmed nocturnal hypoglycaemia was shown in patients with type 2 diabetes treated with basal insulin in combination with either non-insulin anti-hyperglycaemic medicinal product (18% risk reduction) or mealtime insulin (21% risk reduction) during the period from week 9 to end of study period.
Superiornost zdravila Toujeo nad insulinom glargin 100 enot/ml za znižanje tveganja za potrjene hipoglikemije so dokazali pri bolnikih s sladkorno boleznijo tipa 2, ki so prejemali bazalni insulin v kombinaciji ali z neinsulinskimi antihiperglikemičnimi zdravili (18 % zmanjšanje tveganja) ali insulinom ob obrokih (21 % zmanjšanje tveganja) v obdobju od 9. tedna do konca obdobja študije.
Only use needles that are compatible for use with Toujeo DoubleStar (e.g. needles from BD, Ypsomed, Artsana or Owen Mumford) that are 8 mm long or shorter.
Uporabljajte samo igle, ki primerne za uporabo z zdravilom Toujeo DoubleStar (npr. igle izdelovalcev BD, Ypsomed, Artsana ali Owen Mumford) in niso daljše od 8 mm.
A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.
Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka insulina glargin.
Rarely, insulin may cause oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.
Redko lahko insulin povzroči edeme, še zlasti, če intenzivirano insulinsko zdravljenje izboljša presnovno urejenost, ki je bila prej slaba.
- Switching from once-daily basal insulins to once-daily Toujeo can be done unit-to-unit based on the previous basal insulin dose.
- Prehod z bazalnih insulinov enkrat na dan na zdravilo Toujeo enkrat na dan je mogoče izvesti na podlagi enote-za-enoto predhodno uporabljanega odmerka bazalnega insulina.
Switch between other insulins and Toujeo
Prehod med drugimi insulini in zdravilom Toujeo
Hypoglycaemia (low blood sugar levels)
Hipoglikemija (nizka koncentracija krvnega sladkorja)
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism (see section 4.8).
Bolnikom z okvaro ledvic se lahko potreba po insulinu zmanjša zaradi zmanjšane presnove insulina (glejte poglavje 4.8).
Zinc chloride, metacresol, glycerol, hydrochloric acid / sodium hydroxide (for pH adjustment), water for injections.
Cinkov klorid, metakrezol, glicerol, klorovodikova kislina / natrijev hidroksid (za prilagoditev pH), voda za injekcije.
The strength “300” is highlighted in honey gold on the label of your Toujeo SoloStar pre-filled pen.
Jakost »300« je poudarjena v medeno zlati barvi na ovojnini vašega Toujeo SoloStar napolnjenega peresnika.
Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Toujeo.
Bolnikom, ki zaradi protiteles proti humanemu insulinu potrebujejo velike odmerke insulina, se lahko z zdravilom Toujeo izboljša odziv na insulin.
When switching basal insulin to Toujeo, dose reduction of basal and bolus insulin needs to be considered on an individual basis, in order to mimimize the risk of hypoglycaemia (see section 4.4).
Pri prehodu z bazalnega insulina na zdravilo Toujeo je treba individualno razmisliti o manjši potrebi po bazalnem in bolusnem insulinu, da bi zmanjšali tveganje za hipoglikemijo (glejte poglavje 4.4).
• Take care when handling needles - this is to prevent needle injury and cross-infection.
• Pri ravnanju z iglami bodite previdni, da boste preprečili poškodbe z iglo in navzkrižno okužbo.
- When switching from Toujeo to insulin glargine 100 units/ml, the dose should be reduced (approximately by 20%) to reduce the risk of hypoglycaemia.
- Pri prehodu z zdravila Toujeo na insulin glargin 100 enot/ml je treba odmerek zmanjšati (za približno 20%), da bi zmanjšali tveganje za hipoglikemijo.
Results from studies comparing Toujeo and insulin glargine 100 units/ml did not indicate any difference in term of development of anti-insulin antibodies, on efficacy, safety or dose of basal insulin between Toujeo and insulin glargine 100 units/ml.
Rezultati študij, ki so primerjale zdravilo Toujeo z insulinom glargin 100 enot/ml, niso pokazali razlik, kar zadeva nastanek proti insulinskih protiteles, učinkovitost, varnost ali odmerek bazalnega insulina med zdravilom Toujeo in insulinom glargin 100 enot/ml.
Your blood sugar level may either rise or fall if you take:
Krvni sladkor se vam lahko zviša ali vam pade, če jemljete:
• Read the Instructions for Use that come with this package leaflet.
• Preberite navodila, priložena temu navodilu za uporabo.
26 weeks of treatment Patients previously treated with basal insulin
26 tednov zdravljenja Bolniki, predhodno zdravljeni z bazalnim insulinom
Toujeo can be used in elderly people, renal and hepatic impaired patients, and children and adolescents from the age of 6 years.
Zdravilo Toujeo se lahko uporablja pri starejših osebah in bolnikih z okvaro ledvic ali jeter, mladostnikih in otrocih od 6. leta starosti naprej.
After subcutaneous injection of Toujeo, the intra-subject variability, defined as the coefficient of variation for the insulin exposure during 24 hours was low at steady state (17.4%).
Po subkutanem injiciranju zdravila Toujeo je bila intraindividualna variabilnost, izražena s koeficientom variacije izpostavljenosti insulinu v teku 24 ur, v stanju dinamičnega ravnovesja majhna
Packs of 1, 3, 6 (2 packs of 3), 9 (3 packs of 3) and 10 pens are available.
Na voljo so pakiranja z 1, 3, 6 (2 pakiranja po 3), 9 (3 pakiranja po 3) in 10 peresniki.
This is to avoid dosing errors and potential overdose which may lead to low blood sugar.
To lahko vodi v napake pri odmerjanju in do previsokega odmerka, kar lahko znatno zniža raven sladkorja v krvi.
No dose re-calculation is required.
Dodatno preračunavanje odmerka ni potrebno.
• Disopyramide - for some heart problems.
• Dizopiramid - za zdravljenje določenih težav s srcem.
• Your blood sugar is often too low.
• Imate pogosto prenizek krvni sladkor.
• Inject it into the front of your thighs, upper arms or the front of your waist (abdomen).
• Injicirajte ga v sprednji del stegen, nadlakti ali sprednji del trebuha.
The efficacy and safety of Toujeo have been studied in a 1:1 randomized controlled open label clinical trial in children and adolescents with type 1 diabetes mellitus for a period of 26 weeks (n=463).
Učinkovitost in varnost zdravila Toujeo so v obdobju 26 tednov raziskali v randomiziranem (razmerje 1:1), z zdravilno učinkovino nadzorovanem odprtem kliničnem preskušanju pri otrocih in mladostnikih s sladkorno boleznijo tipa 1 (n = 463).
29 units selected
izbrani odmerek 29 enot
• If you are blind or have poor eye sight, do not use the pre-filled pen without help.
• Če ste slepi ali slabo vidite, napolnjenega injekcijskega peresnika ne uporabljajte brez pomoči, ker ne boste mogli prebrati odmernega okenca na peresniku.
Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment.
Posebej skrbno je treba nadzirati dejavnike, ki povečujejo nagnjenost k hipoglikemiji, in potrebna je lahko prilagoditev odmerka.
A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Izrazita sprememba urejenosti glikemije lahko prehodno poslabša vid zaradi prehodno spremenjenega turgorja in lomnega količnika leče.
With Toujeo, it may take longer to recover from low blood sugar because it is long-acting.
Z zdravilom Toujeo lahko traja dalj časa, da nizek krvni sladkor mine, ker gre za dolgodelujoče zdravilo.
Initiation
Uvedba
If you don't, your full dose will not be delivered.
Če tega ne naredite, se lahko zgodi, da ne prejmete celotnega odmerka.
When switching from a treatment regimen with an intermediate or long-acting insulin to a regimen with Toujeo, a change of the dose of the basal insulin may be required and the concomitant anti-hyperglycaemic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of non-insulin anti-hyperglycaemic medicinal products).
Pri prehodu s srednjedolgo- ali dolgodelujočega insulina na zdravljenje z zdravilom Toujeo sta lahko potrebni sprememba odmerka bazalnega insulina in prilagoditev sočasnega antihiperglikemičnega zdravljenja (odmerek in časovni razpored dodatnih običajnih insulinov ali hitrodelujočih insulinskih analogov oz. odmerek neinsulinskih antihiperglikemičnih zdravil).
It is used to treat diabetes mellitus in adults, adolescents and children from the age of 6 years.
To zdravilo se uporablja za zdravljenje sladkorne bolezni pri odraslih, mladostnikih in otrocih od 6. leta starosti naprej.
STEP 5: Inject your dose
KORAK: Injicirajte odmerek
Beta-blockers
Zaviralci beta
If you have missed a dose of Toujeo or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia):
Če ste izpustili odmerek zdravila Toujeo ali niste injicirali dovolj insulina, se vam lahko krvni sladkor preveč zviša (hiperglikemija).
Although Toujeo contains the same active substance as insulin glargine 100 units/ml, these medicines are not interchangeable.
Zdravilo Toujeo sicer vsebuje isto učinkovino kot insulin glargin 100 enot/ml, vendar ti zdravili nista medsebojno zamenljivi.
The product may be stored for a maximum of 6 weeks below 30°C.
Zdravilo se shranjuje največ 6 tednov na temperaturi do 30 °C.
If this occurs, patients should increase the frequency of checking their blood glucose levels and might need to administer additional insulin.
V takšnem primeru si morajo bolniki pogosteje meriti koncentracijo glukoze v krvi in morda potrebujejo dodatni insulin.
- Switching from twice-daily basal insulins to once-daily Toujeo, the recommended initial Toujeo dose is 80% of the total daily dose of basal insulin that is being discontinued.
- Pri prehodu z bazalnih insulinov dvakrat na dan na zdravilo Toujeo enkrat na dan je priporočeni začetni odmerek zdravila Toujeo 80 % celotnega dnevnega odmerka bazalnega insulina, ki ga je bolnik uporabljal dotlej.
• Other: The Guide for healthcare professionals is also highlighting the distinction between the different Toujeo presentations: That insulin glargine 300 units/ml is available in two different presentations: Toujeo SoloStar (1.5 mL prefilled pen/450 units) and Toujeo DoubleStar (3 mL prefilled pen/900 units).
• Drugo: Vodnik za zdravstvene delavce izpostavlja tudi razlikovanje med različnimi oblikami zdravila Toujeo: Da je insulin glargin 300 enot/ml na voljo v dveh različnih oblikah: Toujeo SoloStar (1,5-ml napolnjen injekcijski peresnik/450 enot) in Toujeo DoubleStar (3-ml napolnjen injekcijski peresnik/900 enot).
- That dose adjustment is needed when patients are switched from one to the other strength: After titration, on average a 10-18% higher basal insulin dose are needed to achieve target ranges for plasma glucose levels when using the 300 units/ml formulation compared to the 100 units/ml formulation.
- V primeru prehoda bolnika z ene jakosti na drugo je treba prilagoditi odmerek: Pri uporabi oblike s 300 enot/ml je po titriranju za doseganje ciljnega območja koncentracije glukoze v plazmi potreben povprečno od 10 do 18 % večji odmerek bazalnega insulina kot pri obliki 100 enot/ml.
• For more information, see the box at the end of this leaflet.
• Za več informacij glejte okvir na koncu tega navodila.
Packs of 1, 3, 5 and 10 pens are available.
Na voljo so pakiranja z 1, 3, 5 in 10 peresniki.
A Select 4 units by turning the dose selector until the dose pointer is at the 4 mark.
A Nastavite 4 enote tako, da zavrtite izbirnik odmerka, dokler kazalnik odmerka ne kaže oznake 4.
Physiological concentrations of endogenous IGF-1 may activate the mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy,
Fiziološke koncentracije endogenega IGF-1 lahko aktivirajo mitogenoproliferacijsko pot.
Before using Toujeo SoloStar or Toujeo DoubleStar pre-filled pen, the Instructions for Use included in the package leaflet must be read carefully.
Pred uporabo napolnjenega injekcijskega peresnika Toujeo SoloStar ali Toujeo DoubleStar mora bolnik natančno prebrati navodila z uporabo, navedena na priloženem navodilu za uporabo.
• Serious low blood sugar may cause brain damage and may be life-threatening.
• Resno znižanje krvnega sladkorja lahko povzroči okvaro možganov in je lahko smrtno nevarno.
In the event of blocked needle, the patients must follow the instructions described in Step 3 of the Instructions for Use accompanying the package leaflet (see section 6.6).
Če je igla zamašena, mora bolnik upoštevati navodila, opisana v 3. koraku navodil, priloženih navodilu za uporabo zdravila (glejte poglavje 6.6).
When changing from Toujeo SoloStar to Toujeo DoubleStar, if the patient's previous dose was an odd number (e.g. 23 units) then the dose must be increased or decreased by 1 unit (e.g. 24 or 22 units).
Če je bil bolnikov prejšnji odmerek liho število (npr. 23 enot), je treba odmerek ob prehodu z zdravila Toujeo SoloStar na zdravilo Toujeo DoubleStar povečati ali zmanjšati za 1 enoto (npr. na 24 ali 22 enot).
Examples of signs that your blood sugar level is falling too much or too fast include: sweating, clammy skin, feeling anxious, fast or irregular heart beat, high blood pressure and palpitations.
Med znaki pretiranega ali prehitrega znižanja krvnega sladkorja so: znojenje, vlažna in lepljiva koža, občutek tesnobe, hitro ali neredno bitje srca, visok krvni tlak in razbijanje srca (palpitacije).
Results from all clinical trials with Toujeo indicated that reductions in HbA1c from baseline to end of trial were non-inferior to insulin glargine 100 units/ml.
Rezultati vseh kliničnih preskušanj z zdravilom Toujeo so pokazali, da znižanje HbA1c od izhodišča do konca preskušanja ni bilo inferiorno v primerjavi z insulinom glargin 100 enot/ml.
You can select doses from 2 to 160 units in steps of 2 units at a time.
Izberete lahko odmerke od 2 do 160 enot v korakih po 2 enoti naenkrat.
• Read all of these instructions before using your pen.
• Pred uporabo peresnika preberite vsa ta navodila.
This is because there is no experience with Toujeo in this age group.
Z zdravilom Toujeo namreč v tej starostni skupini ni izkušenj.
However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy.
Vendar se lahko z intenziviranjem insulinskega zdravljenja in nenadnim izboljšanjem urejenosti glikemije diabetična retinopatija prehodno poslabša.
RR: 1.00 [0.95;1.04]
RT: 1,00 [0,95;1,04]
Table 2: Results from clinical trials in type 2 diabetes mellitus
Preglednica 2: Rezultati kliničnih preskušanj pri sladkorni bolezni tipa 2
• When insulin comes out of the needle tip, your pen is working correctly.
• Če iz konice igle pride insulin, peresnik deluje pravilno.